Monday, 20 December 2021


European Medicines Agency, Amsterdam, the Netherlands

This extraordinary meeting is organised to discuss the evaluation of the conditional marketing authorisation application for Nuvaxovid (also known as NVX-CoV2373), a COVID-19 vaccine developed by Novavax.

EMA will communicate on the outcome of the meeting. 

The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the European Medicines Agency's opinions on all questions concerning human medicines.

How useful do you find this page?